DK1272666T3 - Et funktionsassay for höjdensitetslipoprotein - Google Patents

Et funktionsassay for höjdensitetslipoprotein

Info

Publication number
DK1272666T3
DK1272666T3 DK01923023T DK01923023T DK1272666T3 DK 1272666 T3 DK1272666 T3 DK 1272666T3 DK 01923023 T DK01923023 T DK 01923023T DK 01923023 T DK01923023 T DK 01923023T DK 1272666 T3 DK1272666 T3 DK 1272666T3
Authority
DK
Denmark
Prior art keywords
oxidised
phospholipid
mammal
high density
density lipoprotein
Prior art date
Application number
DK01923023T
Other languages
Danish (da)
English (en)
Inventor
Alan M Fogelman
Mohamad Navab
Susan Hama
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/541,468 external-priority patent/US6596544B1/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1272666T3 publication Critical patent/DK1272666T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
DK01923023T 2000-03-31 2001-03-29 Et funktionsassay for höjdensitetslipoprotein DK1272666T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53956900A 2000-03-31 2000-03-31
US09/541,468 US6596544B1 (en) 2000-03-31 2000-03-31 Functional assay of high-density lipoprotein

Publications (1)

Publication Number Publication Date
DK1272666T3 true DK1272666T3 (da) 2006-02-27

Family

ID=27066136

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01923023T DK1272666T3 (da) 2000-03-31 2001-03-29 Et funktionsassay for höjdensitetslipoprotein

Country Status (9)

Country Link
EP (3) EP1274862A4 (fr)
JP (2) JP4675539B2 (fr)
AT (1) ATE306563T1 (fr)
AU (3) AU4976101A (fr)
CA (2) CA2404350A1 (fr)
DE (1) DE60113976T2 (fr)
DK (1) DK1272666T3 (fr)
ES (1) ES2250378T3 (fr)
WO (2) WO2001075168A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
EP2218736A1 (fr) 2004-10-15 2010-08-18 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Implants revêtus de peptides hélicoidaux amphipathiques à plusieurs domaines et leurs méthodes d'utilisation
AU2006274477B2 (en) * 2005-07-27 2011-05-12 Technische Universitat Graz Oxidised phospholipids comprising a fluorophore moiety and use in the determination of the presence of enzymes having antiatherogenetic activity
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
DK2682400T5 (da) 2007-08-28 2017-11-27 Uab Research Foundation Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
RU2532546C2 (ru) 2008-11-06 2014-11-10 Васкьюлар Байодженикс Лтд. Окисленные соединения липидов и их применение
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
WO2016084023A1 (fr) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Lipides oxydés et traitement ou prévention de la fibrose
US10905736B2 (en) 2016-09-28 2021-02-02 The Regents Of The University Of California Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
JP7084590B2 (ja) * 2016-10-31 2022-06-15 国立大学法人大阪大学 脂質異常症治療が必要な被検者の選別方法及び選別用試薬
WO2018165574A1 (fr) * 2017-03-10 2018-09-13 The Regents Of The University Of California Procédé de diagnostic du risque de maladie inflammatoire par profilage de glycane
WO2021172380A1 (fr) * 2020-02-25 2021-09-02 株式会社Ｌｓｉメディエンス Procédé d'analyse de médicaments d'acide nucléique

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5820932Y2 (ja) * 1979-01-27 1983-05-02 財団法人杉山産業化学研究所 過酸化脂質測定のためのｔｂａ試験紙
JPS56117798A (en) * 1980-02-21 1981-09-16 Toyo Jozo Co Ltd Kit for measuring lipoid peroxide
JPS60133368A (ja) * 1983-12-19 1985-07-16 Dai Ichi Pure Chem Co Ltd 免疫測定方法
JPH01231897A (ja) * 1988-03-11 1989-09-18 Fuji Photo Film Co Ltd 乾式グルコース分析要素
US5135716A (en) * 1989-07-12 1992-08-04 Kingston Diagnostics, L.P. Direct measurement of HDL cholesterol via dry chemistry strips
WO1994023302A1 (fr) * 1993-04-07 1994-10-13 The Australian National University Dosage immunologique de lipoproteines humaines a faible densite modifiees par oxydation presentes dans le plasma
RU94044169A (ru) * 1994-12-16 1996-10-20 И.А. Кочетов Многослойный аналитический элемент
US5958714A (en) * 1996-10-02 1999-09-28 Safety Associates, Inc. Test kits for determining at least two specific analytes in foods and other complex matrices
WO1998020897A1 (fr) * 1996-11-15 1998-05-22 President And Fellows Of Harvard College Modulation de map kinase phosphatase 1 (mkp-1)
JP3428853B2 (ja) * 1997-04-02 2003-07-22 東北電子産業株式会社 液体試料の抗酸化力を測定するための方法および装置
WO1998059248A1 (fr) * 1997-06-20 1998-12-30 Leuven Research & Development Vzw Dosages, anticorps et etalons de detection de lipoproteines de basse densite, oxydees et modifiees par mda
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase

Also Published As

Publication number Publication date
EP1650312A2 (fr) 2006-04-26
EP1272666B1 (fr) 2005-10-12
DE60113976T2 (de) 2006-07-27
AU4976201A (en) 2001-10-15
JP2003529375A (ja) 2003-10-07
AU4976101A (en) 2001-10-15
AU2001249762B2 (en) 2006-03-30
ES2250378T3 (es) 2006-04-16
EP1272666A4 (fr) 2004-09-22
JP2003529775A (ja) 2003-10-07
CA2404000A1 (fr) 2001-10-11
JP4675539B2 (ja) 2011-04-27
ATE306563T1 (de) 2005-10-15
DE60113976D1 (de) 2006-02-23
EP1272666A1 (fr) 2003-01-08
EP1274862A1 (fr) 2003-01-15
CA2404000C (fr) 2010-07-27
CA2404350A1 (fr) 2001-10-11
EP1274862A4 (fr) 2005-06-22
EP1650312A3 (fr) 2006-05-17
WO2001075170A1 (fr) 2001-10-11
WO2001075168A1 (fr) 2001-10-11

Similar Documents

Publication Publication Date Title
DK1272666T3 (da) Et funktionsassay for höjdensitetslipoprotein
DK0753583T3 (da) Fremgangsmåde til kvantitativ analyse af cholesterol
DK0659275T3 (da) Analytisk testapparat med indbygget negativ og positiv kontrol
NO176293C (no) Metode for å bestemme en ligand i en pröve ved bruk av en optisk bölgeleder og en anordning for utförelse av metoden
GB2365526B (en) Assay apparatus for measuring the amount of an analyte in a biological or environmental sample
CY1105245T1 (el) Μεθοδος προεπεξepγασιας δειγματος για επιμετρηση χοληστepολης και μεθοδος επιμετρησης χοληστepολης σε συγκεκριμενες λιποπρωτεϊνες χρησιμοποιωντας αυτη τη μεθοδο
DE60204418D1 (de) "High-Density-Lipoprotein"-Testvorrichtung und Verfahren
PT975974E (pt) Ensaio utilizando particulas magneticas
KR890702039A (ko) 1,25-디하이드록시 비타민 d의 분석 방법
DE60233107D1 (de) Teststreifen enthaltend Kontrollmittel und Zeitsetzermittel
ES2161011T3 (es) Reactivos para ensayo de ion diazonio y metodos para su utilizacion.
BR9507261A (pt) Processo para detectar a presença de um analito em uma amostra de saliva solução de tensoativo adequada para uso no mesmo e kit
ATE534903T1 (de) Latex-reaktionsmittel zur adiponectinanalyse und verfahren zur adiponectinanalyse
ATE278950T1 (de) Verwendung von annexinen als lupus antikoagulans kontrolle oder standard in gerinnungstesten
DE59907982D1 (de) Verfahren zum Nachweis einer bei Apoptose aktivierten Protease
DK0790494T3 (da) Flerlaget testmiddel
TR200402619T4 (tr) İdrardaki redoks durumunun tespiti için kit ve yöntem.
NO175024C (no) Agglutineringsreagens og dets anvendelse for detektering av et antigen, antistoffer eller andre analytter, samt prövesett omfattende reagensen
DK1156121T3 (da) Urin-trypsininhibitorer-assay indeholdende et chelateringsmiddel
DK563588A (da) Proevningsapparat til brug ved proevning for en analysand
BR9914294A (pt) Dispositivo de medição da atividade enzimática de amostra alimentar sólida, sua utilização e processo de medida da atividade enzimática de um alimento
Onifade et al. Evaluating the Analytical Performance of MicroTip (TM) Technology on the VITROS® 5, 1 FS Chemistry System
O'Connell Development of an Atomic Force Microscopic Immunosensor for the Ferritin Antigen
Stewart et al. S5: Conducting a Relative Fluorescence Assay with the OPN Fluorometer
刘皓 et al. Effects of Glucagon and Dibutyryl cAMP on Secretion of Apolipoproteins A Ⅰ, A Ⅱ, B100, CⅢ and E by Cultured HepG2 Cells